IQVIA Holdings Inc
IQV: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$448.00 | Dtbzzdx | Cmxbqyvy |
Positive Long-Term Outlook for IQVIA as Clinical Trial Outsourcing Demand Drives Growth
Business Strategy and Outlook
IQVIA (formerly QuintilesIMS) is the result of the merger of Quintiles, a leading late-stage contract research organization, or CRO, and IMS Health, a dominant player in life sciences data and analytics. The combined company has become a leader among CROs and in the life sciences data and analytics industry. Further, as a result of the merger, the company leads in real-world evidence, in which data from sources such as patient records or medical claims can be used to create clinical evidence for regulatory approval.